133865-89-1

133865-89-1 structure

Name: Safinamide
Chemical Name: (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
CAS Number: 133865-89-1
Molecular Formula: C₁₇H₁₉FN₂O₂
Molecular Weight: 302.343
Catalog: Biochemical Inhibitor Metabolism MAO inhibitor
Create Date: 2018-04-03 08:00:00
Modify Date: 2025-08-26 11:37:07
Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals.

Name	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
Synonyms	(S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide Safinamide N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide (2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide ZVY1&M1R DO1R CF &&L or S Form Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-

Description	Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals.
Related Catalog	Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease
References	[1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. [2]. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010 Sep;11(13):2261-8. [3]. Onofrj M, et al. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. [4]. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007 Jul;8(7):570-9. [5]. Dal Bo L, et al. Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittelforschung. 2006;56(12):814-9. http://www.ncbi.nlm.nih.gov/pubmed/17260668

Density	1.2±0.1 g/cm3
Boiling Point	476.7±40.0 °C at 760 mmHg
Melting Point	208-212°
Molecular Formula	C₁₇H₁₉FN₂O₂
Molecular Weight	302.343
Flash Point	242.1±27.3 °C
Exact Mass	302.143066
PSA	64.35000
LogP	2.37
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.570

Hazard Codes	Xi
RTECS	TX1457385

66742-57-2

33208-99-0

~87%

133865-89-1

Literature: NEWRON PHARMACEUTICALS S.P.A. Patent: WO2009/74478 A1, 2009 ; Location in patent: Page/Page column 60-62 ;

1000370-31-9

~92%

133865-89-1

Literature: NEWRON PHARMACEUTICALS S.P.A. Patent: WO2007/147491 A1, 2007 ; Location in patent: Page/Page column 34-35 ;

7324-05-2

66742-57-2

~89%

133865-89-1

Literature: NEWRON PHARMACEUTICALS S.P.A. Patent: WO2007/147491 A1, 2007 ; Location in patent: Page/Page column 32 ;

66742-57-2

80222-96-4

133865-89-1

174756-44-6

Literature: WO2009/74478 A1, ; Page/Page column 71-72 ;

66742-57-2

33208-99-0

133865-89-1

174756-44-6

Literature: WO2009/74478 A1, ; Page/Page column 64-65 ;

35661-39-3

456-47-3

211617-68-4

133865-89-1

Literature: Journal of Medicinal Chemistry, , vol. 50, # 20 p. 4909 - 4916

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

133866-14-5	133865-89-1
1147299-69-1	1147299-71-5
2748522-33-8	202825-46-5
1569545-21-6	1892179-13-3
1572398-22-1	1898076-20-4
1601977-08-5	1690428-17-1
1594798-36-3	1891512-00-7
1892030-21-5	1000542-04-0